BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

426 related articles for article (PubMed ID: 33934412)

  • 21. Faecal microbiota transplantation to prevent complications after allogeneic stem cell transplantation for haematological malignancies: a study protocol for a randomised controlled phase-II trial (the FMT-allo study).
    Dougé A; Ravinet A; Corriger A; Cabrespine A; Wasiak M; Pereira B; Sokol H; Nguyen S; Bay JO
    BMJ Open; 2023 May; 13(5):e068480. PubMed ID: 37130682
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
    Petersen SL
    Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of GVHD on the gut and intestinal microflora.
    Ji H; Feng S; Liu Y; Cao Y; Lou H; Li Z
    Transpl Immunol; 2024 Feb; 82():101977. PubMed ID: 38184214
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Third-party fecal microbiota transplantation for high-risk treatment-naïve acute GVHD of the lower GI tract.
    DeFilipp Z; Damania AV; Kim HT; Chang CC; El-Jawahri A; McAfee SL; Bottoms AS; Toncheva V; Smith MM; Dolaher M; Perry L; White M; Diana B; Connolly S; Dey BR; Frigault MJ; Newcomb RA; O'Donnell PV; Spitzer TR; Mansour MK; Weber D; Ajami NJ; Hohmann E; Jenq RR; Chen YB
    Blood Adv; 2024 May; 8(9):2074-2084. PubMed ID: 38471063
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Longitudinal relationship between the gut microbiota variation and diversity and gut graft-versus-host disease (GVHD) following pediatric allogeneic hematopoietic cell transplantation (HCT) - Case series.
    Gray AN; Tobin NH; Moore TB; Li F; Aldrovandi GM
    Int J Med Microbiol; 2023 May; 313(3):151580. PubMed ID: 37121094
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Stool Microbiota at Neutrophil Recovery Is Predictive for Severe Acute Graft vs Host Disease After Hematopoietic Cell Transplantation.
    Golob JL; Pergam SA; Srinivasan S; Fiedler TL; Liu C; Garcia K; Mielcarek M; Ko D; Aker S; Marquis S; Loeffelholz T; Plantinga A; Wu MC; Celustka K; Morrison A; Woodfield M; Fredricks DN
    Clin Infect Dis; 2017 Nov; 65(12):1984-1991. PubMed ID: 29020185
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Dental Biofilm Microbiota Dysbiosis Is Associated With the Risk of Acute Graft-
    Heidrich V; Bruno JS; Knebel FH; de Molla VC; Miranda-Silva W; Asprino PF; Tucunduva L; Rocha V; Novis Y; Arrais-Rodrigues C; Fregnani ER; Camargo AA
    Front Immunol; 2021; 12():692225. PubMed ID: 34220852
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The Potential Roles of Mucosa-Associated Invariant T Cells in the Pathogenesis of Gut Graft-Versus-Host Disease After Hematopoietic Stem Cell Transplantation.
    Gao MG; Hong Y; Zhao XY; Pan XA; Sun YQ; Kong J; Wang ZD; Wang FR; Wang JZ; Yan CH; Wang Y; Huang XJ; Zhao XS
    Front Immunol; 2021; 12():720354. PubMed ID: 34539656
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Treating Steroid Refractory Intestinal Acute Graft-vs.-Host Disease With Fecal Microbiota Transplantation: A Pilot Study.
    Qi X; Li X; Zhao Y; Wu X; Chen F; Ma X; Zhang F; Wu D
    Front Immunol; 2018; 9():2195. PubMed ID: 30319644
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Targeting the gut microbiome: An emerging trend in hematopoietic stem cell transplantation.
    Ciernikova S; Kasperova B; Drgona L; Smolkova B; Stevurkova V; Mego M
    Blood Rev; 2021 Jul; 48():100790. PubMed ID: 33573867
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Intestinal Microbiota Influence Immune Tolerance Post Allogeneic Hematopoietic Cell Transplantation and Intestinal GVHD.
    Köhler N; Zeiser R
    Front Immunol; 2018; 9():3179. PubMed ID: 30705680
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Metagenomic analysis of the stool microbiome in patients receiving allogeneic stem cell transplantation: loss of diversity is associated with use of systemic antibiotics and more pronounced in gastrointestinal graft-versus-host disease.
    Holler E; Butzhammer P; Schmid K; Hundsrucker C; Koestler J; Peter K; Zhu W; Sporrer D; Hehlgans T; Kreutz M; Holler B; Wolff D; Edinger M; Andreesen R; Levine JE; Ferrara JL; Gessner A; Spang R; Oefner PJ
    Biol Blood Marrow Transplant; 2014 May; 20(5):640-5. PubMed ID: 24492144
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Fecal microbiota transplantation for patients with steroid-resistant acute graft-versus-host disease of the gut.
    Kakihana K; Fujioka Y; Suda W; Najima Y; Kuwata G; Sasajima S; Mimura I; Morita H; Sugiyama D; Nishikawa H; Hattori M; Hino Y; Ikegawa S; Yamamoto K; Toya T; Doki N; Koizumi K; Honda K; Ohashi K
    Blood; 2016 Oct; 128(16):2083-2088. PubMed ID: 27461930
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The intestinal microbiota in allogeneic hematopoietic cell transplant and graft-versus-host disease.
    Staffas A; Burgos da Silva M; van den Brink MR
    Blood; 2017 Feb; 129(8):927-933. PubMed ID: 27940475
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Antibiotic use and ileocolonic immune cells in patients receiving fecal microbiota transplantation for refractory intestinal GvHD: a prospective cohort study.
    Spindelboeck W; Halwachs B; Bayer N; Huber-Krassnitzer B; Schulz E; Uhl B; Gaksch L; Hatzl S; Bachmayr V; Kleissl L; Kump P; Deutsch A; Stary G; Greinix H; Gorkiewicz G; Högenauer C; Neumeister P
    Ther Adv Hematol; 2021; 12():20406207211058333. PubMed ID: 34987741
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Abnormal Intestinal Microbiome in Medical Disorders and Potential Reversibility by Fecal Microbiota Transplantation.
    DuPont HL; Jiang ZD; DuPont AW; Utay NS
    Dig Dis Sci; 2020 Mar; 65(3):741-756. PubMed ID: 32008133
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Randomized Double-Blind Phase II Trial of Fecal Microbiota Transplantation Versus Placebo in Allogeneic Hematopoietic Cell Transplantation and AML.
    Rashidi A; Ebadi M; Rehman TU; Elhusseini H; Kazadi D; Halaweish H; Khan MH; Hoeschen A; Cao Q; Luo X; Kabage AJ; Lopez S; Holtan SG; Weisdorf DJ; Khoruts A; Staley C
    J Clin Oncol; 2023 Dec; 41(34):5306-5319. PubMed ID: 37235836
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Healthcare resource utilization and costs associated with acute graft-versus-host disease following allogeneic hematopoietic cell transplantation.
    Yu J; Lal L; Anderson A; DuCharme M; Parasuraman S; Weisdorf D
    Support Care Cancer; 2020 Nov; 28(11):5491-5499. PubMed ID: 32172407
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Microbiome: An Emerging New Frontier in Graft-Versus-Host Disease.
    Kumari R; Palaniyandi S; Hildebrandt GC
    Dig Dis Sci; 2019 Mar; 64(3):669-677. PubMed ID: 30523482
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Acute Steroid-Refractory Gastrointestinal Graft-Versus-Host Disease Is Not Associated With Significant Differences in Gut Taxonomic Composition Compared to Steroid-Sensitive Gastrointestinal Graft-Versus-Host Disease Immediately Before Onset of Disease.
    Zeng K; Brewster R; Kang JB; Tkachenko E; Brooks E; Bhatt AS; Fodor AA; Andermann TM
    Transplant Cell Ther; 2024 Feb; 30(2):237.e1-237.e9. PubMed ID: 37944820
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.